KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Average: 2011-2024

Historic Equity Average for TherapeuticsMD (TXMD) over the last 14 years, with Dec 2024 value amounting to $28.3 million.

  • TherapeuticsMD's Equity Average fell 0.05% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year decrease of 0.05%. This contributed to the annual value of $28.3 million for FY2024, which is 12.06% down from last year.
  • TherapeuticsMD's Equity Average amounted to $28.3 million in FY2024, which was down 12.06% from $32.2 million recorded in FY2023.
  • TherapeuticsMD's 5-year Equity Average high stood at $32.2 million for FY2023, and its period low was -$108.8 million during FY2021.
  • Its 3-year average for Equity Average is $10.4 million, with a median of $28.3 million in 2024.
  • In the last 5 years, TherapeuticsMD's Equity Average plummeted by 207.57% in 2020 and then spiked by 210.18% in 2023.
  • Over the past 5 years, TherapeuticsMD's Equity Average (Yearly) stood at -$57.4 million in 2020, then crashed by 89.57% to -$108.8 million in 2021, then skyrocketed by 73.13% to -$29.2 million in 2022, then surged by 210.18% to $32.2 million in 2023, then decreased by 12.06% to $28.3 million in 2024.